Clinical trials: Chronic Versus Graft Host Disease
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Graft-Versus-Host Disease
Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease
The aim of the study is to evaluate the safety and efficacy of mesenchymal stromal cells as treatment for steroid-refractory chronic graft-versus-host disease.
- Trial name
- NCT01522716
- Testing
- Mesenchymal stromal cells
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Karolinska Institutet
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03533816
- Testing
- EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion)
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Kansas Medical Center
Graft Vs Host Disease
Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease
cGVHD is a systemic disease with multi-system damage similar to autoimmune and other immune diseases. It can affect multiple organs such as skin, liver, kidney, and peripheral nerves, causing a serious decline in the quality of…
- Trial name
- NCT05152160
- Testing
- Umbilical Cord Mesenchymal Stem Cell Therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
Cancer
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
RATIONALE: Donor mesenchymal stem cell infusion may be an effective treatment for acute or chronic graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00361049
- Testing
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Partial-thickness Burn, Ulcer
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes.
- Trial name
- NCT02519621
- Testing
- NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Larry Lavery
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic…
- Trial name
- NCT00224055
- Testing
- Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Watson Pharmaceuticals
Chronic Graft-versus-host Disease (cGVHD)
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of…
- Trial name
- NCT06660355
- Testing
- Ruxolitinib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human…
- Conditions
- Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00406393
- Testing
- Tacrolimus, Methotrexate, Sirolimus
- Where
- 24 sites in United States, France
- Volunteers
- 304 people
- Sponsor
- Medical College of Wisconsin
Chronic Graft Versus Host Disease
Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)
Allogeneic stem cell transplantation was developed to cure many patients with hematological malignancies. It results in the development of graft versus host disease (GVHD) in 30-70% of cases.
- Trial name
- TEP-GVH (NCT02352064)
- Testing
- PET (18-FDG)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Caen
Bronchiolitis Obliterable Syndrome
Longitudinal Pulmonary Chronic Graft-versus-host-disease (GvHD) Assessment in Hematopoietic Stem Cell Transplantation (HSCT) Patients
Prospective observational study on the clinical characteristics of pulmonary graft-versus-host disease in patients after hematopoietic stem cell transplantation.
- Trial name
- NCT07297303
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Chronic Graft-Versus-Host Disease, Immune System Diseases
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
This study aims to evaluate the early chronic GvHD events (first line therapy), if the addition of arsenic trioxide to standard therapy with corticosteroids, with or without cyclosporine, will be effective in controlling chronic…
- Trial name
- GvHD-ATO (NCT02966301)
- Testing
- Arsenic Trioxide Injectable Solution
- Volunteers
- 21 people
- Sponsor
- Medsenic
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT.
- Conditions
- Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
- Trial name
- NCT05121142
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hematologic Malignancies, Acute Myeloid Leukemia
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic…
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02743351
- Testing
- ProTmune, Control Arm
- Where
- 15 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fate Therapeutics
Chronic, Infection
Pulpectomy of Primary Molars With Rotary Instrumentation Versus Manual Instrumentation
One of the major concerns in pediatric dentistry is premature loss of necrotic primary teeth which may cause a deleterious effect on the growth of the facial skeletal complex.
- Trial name
- NCT03964766
- Testing
- Rotary instrumentation, Hand instrumentation
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Cairo University
Graft Versus Host Disease
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or…
- Trial name
- NCT00031824
- Testing
- cyclosporine, hydroxychloroquine, prednisone
- Where
- 104 sites in United States, Australia and 4 more
- Volunteers
- 82 people
- Sponsor
- Children's Oncology Group
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
Prospective, multi-center, randomized, single blind study
- Trial name
- DELIVERY (NCT03277378)
- Testing
- lead placement followed by BurstDR stimulation
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Abbott Medical Devices
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD)…
- Trial name
- NCT03225417
- Testing
- Ixazomib, Tacrolimus, Sirolimus
- Where
- 8 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla